Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
about
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastasesChemotherapy for brain metastases from small cell lung cancerWhole brain radiotherapy for the treatment of multiple brain metastasesBrain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatmentStereotactic radiosurgery (SRS) in the modern management of patients with brain metastasesCognition and resective surgery for diffuse infiltrative glioma: an overviewTreatment Planning and Delivery of Whole Brain Irradiation with Hippocampal Avoidance in RatsMotexafin gadolinium in the treatment of brain metastasesMotexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductaseDosimetric evaluation of intensity-modulated radiotherapy, volumetric modulated arc therapy, and helical tomotherapy for hippocampal-avoidance whole brain radiotherapyNeurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.Voluntary running prevents progressive memory decline and increases adult hippocampal neurogenesis and growth factor expression after whole-brain irradiation.Single brain metastasis: radiosurgery alone compared with radiosurgery plus up-front whole-brain radiotherapy.EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force.Bromines on N-allyl position of cationic porphyrins affect both radio- and photosensitizing properties.Whole brain radiotherapy with a conformational external beam radiation boost for lung cancer patients with 1-3 brain metastasis: a multi institutional studyHippocampal neuron number is unchanged 1 year after fractionated whole-brain irradiation at middle age.A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases.The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report.Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trialSimultaneous in-field boost for patients with 1 to 4 brain metastasis/es treated with volumetric modulated arc therapy: a prospective study on quality-of-lifeMotexafin gadolinium enhances the efficacy of aminolevulinic acid mediated-photodynamic therapy in human glioma spheroids.Cyberknife hypofractionated stereotactic radiosurgery (HSRS) of resection cavity after excision of large cerebral metastasis: efficacy and safety of an 800 cGy × 3 daily fractions regimen.Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches.Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.Early-delayed, radiation-induced cognitive deficits in adult rats are heterogeneous and age-dependent.Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis.Predicting compliance and survival in palliative whole-brain radiotherapy for brain metastases.Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafersBrain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating centerMonitoring and optimising cognitive function in cancer patients: Present knowledge and future directions.Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis.A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery aloneDo patients with very few brain metastases from breast cancer benefit from whole-brain radiotherapy in addition to radiosurgery?Effect of virtual reality on cognitive dysfunction in patients with brain tumor.Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 9Radiosurgery alone versus radiosurgery plus whole-brain irradiation for very few cerebral metastases from lung cancerCognition in patients with newly diagnosed brain metastasis: profiles and implications.
P2860
Q24200466-66FB506B-C610-4E02-983D-58BE09885CB4Q24202771-1E6FEF23-41D5-4709-B44A-17251ED5FCF7Q24245002-8ED77E14-EEE7-43A1-8280-8A7966D24A5EQ26751008-6BC0F597-2C64-4CC1-BC0B-9150C573FD5DQ26768667-F9C69734-F613-420F-B095-7F0FBE14AA50Q27026254-0D0A3B2B-B37A-495C-8680-B690EEE79A3BQ27342045-23451424-76EC-4671-97CA-EEF2C65902B7Q28285963-8E058037-0802-40E4-BA61-2C0AA38C988AQ28567883-0608B493-D028-4B77-912F-A919F879D761Q30300160-04021391-3C97-4A8A-AFF3-D0E79DFA50A2Q30426728-87EF8210-23EB-4805-ADC3-1422FAC1ACCAQ30481789-F99DD9F2-E349-4697-9F6D-A05358217E77Q30497389-3DC6732D-51EB-4EED-95E0-490562515656Q31039691-F79BE26B-B5A9-42D0-90CD-27AE63E78CFCQ33249813-0318CBF6-E1E9-44BC-B600-6631F3E91D12Q33413106-BFAF6942-28C5-4328-A806-DF963C4BFB79Q33532301-BECA655C-FF5E-44C9-B6BD-420C4BA85315Q33585529-6DBE398E-DD81-4144-B0E6-78034FA853C0Q33595608-8FDAA7CF-C2DF-4C6B-8CF8-935B82824BFFQ33599167-17B1B116-986F-41FA-9455-D731A2243034Q33684824-5E696C4A-C2DE-4342-859D-F696F7E3AEC3Q33874477-2B595374-26CA-4D95-A228-EACFBD6DEE83Q33946063-3D5D1760-3959-416F-8572-2D35167965C4Q33975357-47EAA2C0-732B-4698-A682-1BC4CFBE530CQ34006233-62C18073-C997-45FE-9942-91F6404856BFQ34021952-B975B054-2BBF-4869-9917-1AAB6D04D9D9Q34036804-071ADAB3-E988-4668-8A72-91A8894232EBQ34080378-B2237FB0-BDED-4CFF-9A7C-BF771CCED032Q34123319-1F2006B4-8FD5-47BF-8E8C-CD762FE52618Q34134011-7B1929EE-7813-4D11-8878-B8C81E9469F0Q34402645-0B81B755-DECD-47E7-97BF-3F2782C42807Q34552757-60E612E5-91E0-4996-BF40-56F24534DA60Q34604438-2314C213-EF38-4710-8B53-E02F4AB56FA1Q34666843-48F037A9-39E3-4C60-9F57-C905AF63F689Q34671396-E9EB47D6-B457-4452-B9E9-10A6888033A4Q34694385-EF46C968-8CC8-480F-9125-AE8900F98B96Q34791497-7BF81871-ABC6-459C-9DC5-76DBEA54D90FQ34854124-C6BD46BB-CDE0-438B-8A0E-98DC69F1B9F7Q34968883-23354AAC-10A3-48C8-97E7-FDCA61443399Q34972626-CEA7C9FD-753D-4C23-8A45-D602E61DCBBF
P2860
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Neurocognitive function and pr ...... a randomized phase III trial.
@ast
Neurocognitive function and pr ...... a randomized phase III trial.
@en
type
label
Neurocognitive function and pr ...... a randomized phase III trial.
@ast
Neurocognitive function and pr ...... a randomized phase III trial.
@en
prefLabel
Neurocognitive function and pr ...... a randomized phase III trial.
@ast
Neurocognitive function and pr ...... a randomized phase III trial.
@en
P2093
P356
P1476
Neurocognitive function and pr ...... a randomized phase III trial.
@en
P2093
Andrea Bezjak
Christian Carrie
Christina A Meyers
Ian Kunkler
Jacobus Meerwaldt
James Liebmann
Jean-Michel Caudrelier
Jennifer A Smith
Laurie E Gaspar
Markus F Renschler
P304
P356
10.1200/JCO.2004.05.128
P407
P577
2004-01-01T00:00:00Z